Cardiovascular Health

This is a software that uses artificial intelligence to analyze coronary angiography images.

The advantage of this software is to provide faster and more accurate diagnosis of soft plaque or stenosis (narrowing) in the coronary arteries.

• 50% of people will suffer a heart attack
• 70% of these people are considered low risk
• 75% of lesions are responsible for heart attacks caused by mild narrowing of arteries

Using this platform, we can detect and quantify atherosclerosis in people without symptoms before the event happens. Even people with normal coronary calcium scans can still have non-calcified plaque which is more likely to be form a clot than calcified plaque.

A coronary artery calcium (CAC) score is a non-invasive, inexpensive way of measuring the amount of calcium in the coronary arteries of the heart.

Having a score of zero helps ensure lower risk but DOES NOT indicate no plaque is present. However, a higher scores indicated higher risk of having a heart attack.

A multifunction cardiogram (MCG) is a unique non-invasive scan done in the office within 10 minutes that can proactively detect early warning signs for heart conditions and overall metabolic health. This simple tool can detect and correct a potentially life threatening and costly condition years before it presents.

Plaquex therapy restores cell membrane integrity and function. Intravenous Plaquex therapy is the use of naturally occurring phosphatidylcholine into the bloodstream where health fat exchange happens at direct cellular level. Plaquex improves cell function so plaque in the vessel walls can be broken down.

Plaquex also

• reduces LDL, VLDL cholesterol
• Increases HDL
• Improves blood flow
• Potent antioxidant and anti-inflammatory agent.

Chelation therapy is a medical treatment that involves the use of chelating agents to remove heavy metals from the body. It also has promising benefits for treatment of cardiovascular disease.

The idea behind using chelation therapy for cardiovascular disease is that the chelating agents can bind to calcium deposits in the arteries, improve endothelium function and increase release of nitric oxide which allows for improved circulation. This helps reduce risks of strokes and heart attacks.

One of the largest studies currently being done is called TACT2. It is a randomized, double-blind, placebo-controlled trial that will enroll over 2,300 patients with a history of myocardial infarction (heart attack) who are also diabetic or have a high risk of cardiovascular disease. Participants will receive either chelation therapy or a placebo over a period of 40 weeks, and the study will evaluate the occurrence of major adverse cardiovascular events (MACE), such as heart attacks, strokes, and death, as well as the safety of chelation therapy.